Search
This clarifies 1992 world series information isintended bluejay tickets diagnoses to enhance an investor`s overall understanding of the company`s pastfinancial performance and prospects for the future. For example, non-GAAPearnings and earnings per share information is an indication of the company`sbaseline performance before items that are considered by the company to be notreflective of the company`s ongoing results. Use of Non-GAAP Financial InformationThis press release contains non-GAAP financial measures, including non-GAAPearnings and earnings per share information, adjusted to exclude certain costs,expenses, gains and losses and other specified items. The plannedacquisition of Medarex is expected to decrease the company`s earnings per shareby $0.02 to $0.03 in 2009 and $0.07 to $0.09 in 2010. The financial guidance for 2009 and the three-year compound annual growth rateinclude the impact of the company`s acquisition of Medarex but exclude theimpact of any potential future strategic acquisitions and divestitures andfurther assume that the company and its partner, sanofi-aventis, maintain U.S.exclusivity for the PLAVIX® patent through at least 2010. The non-GAAP 2009 guidance and the three-year compound annual growth rateexclude other specified items such as gains or losses from sale of businessesand product lines; from sale of equity investments and from discontinuedoperations; restructuring and other exit costs; accelerated depreciationcharges; asset impairments; charges and recoveries relating to significant legalproceedings; upfront and milestone payments for licensing arrangements; debtretirement costs; impairments to investments; and significant tax events.
2009 GUIDANCEBristol-Myers Squibb has revised the 2009 GAAP EPS guidance to $1.58 to $1.68and raised non-GAAP EPS guidance to $1.95 to $2.05 aj burnett . Key 2009 guidanceassumptions include low single-digit revenue growth (high single digit growthexcluding foreign exchange); a full-year gross margin improvement ofapproximately 200 basis points; advertising and promotion increase in thelow-to-mid single-digit range; marketing, sales and administrative expensedecrease in the low-to-mid single digits; research and development expensegrowth in the mid single-digit range; and an effective tax rate of approximately25% bluejays baseball . Thecollaboration allows Bristol-Myers Squibb to refocus its energies towardlonger-term growth goals for 2014 and beyond, improves the company`s overallfinancial stability while maintaining financial flexibility for the future, andprovides an expected bridge to the company`s new neuroscience products bluejays baseball tickets . portion of the companies` long-standing agreement for thedevelopment and commercialization of ABILIFY from the currently scheduled enddate of November 2012 until the expected loss of exclusivity in April 2015 bluejays cap . The acquisition positions Bristol-Myers Squibb forlong-term leadership in biologics; gives the company full rights to a promisingphase III compound, ipilimumab; significantly expands the company`s oncology andimmunology pipeline and provides access to novel antibody discovery technology. On April 6, the company announced an agreement with Otsuka Pharmaceutical, Ltd.to extend the U.S. The data suggest thatbelatacept may represent a promising therapeutic option for kidney transplantpatients.
* Results of two studies that demonstrated the consistent safety andeffectiveness of ORENCIA over 5 and 7 years of treatment in rheumatoid arthritispatients who have had an inadequate response to methotrexate were presented inJune at the European Congress of Rheumatology (EULAR).STRATEGIC UPDATEOn July 22, Bristol-Myers Squibb and Medarex announced that the companies havesigned a definitive merger agreement providing for the acquisition of Medarex byBristol-Myers Squibb autographed baseball . * On July 20, the company and its partner Eli Lilly and ImClone Systemsannounced that the FDA had approved revisions to the U.S bluejays hat . prescribinginformation for ERBITUX concerning the treatment of patients with an epidermalgrowth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC).The labeling revisions include a modification which states that ERBITUX is notrecommended for patients whose tumors had K-ras mutations in codon 12 or 13 bluejays hats . Anestimated 40 percent of patients with mCRC have K-ras mutations while themajority, approximately 60 percent, has a wild-type K-ras gene.Immunology* At the American Transplant Congress in May, the company presented the resultsof two Phase 3 trials for belatacept, an investigational co-stimulation blockerbeing studied for use in solid organ transplantation bluejays jerseys .
* The company and Exelixis reported encouraging data from an ongoing Phase 2trial of XL184 in patients with previously-treated glioblastoma multiforme, themost common and aggressive form of brain tumor.* In May, the FDA granted full approval for SPRYCEL for the treatment of adultsin all phases of chronic myeloid leukemia (CML) who are resistant or intolerantto prior therapies including Gleevec (imatinib mesylate) SPRYCEL was originallyapproved in 2006 baseball managers . * Based on interim results from two Phase 2 studies in castrate-resistantprostate cancer (CRPC), SPRYCEL (dasatinib) may have potential as a treatmentfor CRPC A Phase 3 study of SPRYCEL in CRPC is currently ongoing bluejays photos . She holds abachelor's degree from Indiana University, Bloomington, and an MBA fromAnderson University, Anderson, Ind bluejay tickets . There were approximately 204.6 million fully dilutedshares outstanding in the second quarter of 2009, versus 170.0 million shares ayear ago bluejays baseball . Second Quarter GAAP Segment ResultsThe Asia/Latin America segment reported net sales of $396.5 million for thesecond quarter of 2009, up from $389.4 million in 2008.
EBIT totaled $146.1million, compared with $119.7 million for the year-ago quarter baseball season tickets . Segmentperformance was driven by double-digit constant dollar sales growth in key Asianmarkets, including China, Thailand and Malaysia, consistent with recorded sharegains across the region bluejays baseball tickets . Segment sales also benefited from double-digit growthin a number of markets in Latin America bluejays cap . The North America/Europe segment reported net sales of $322.8 million for thesecond quarter, down from $339.2 million in 2008 . EBIT totaled $119.0 million,compared with $119.2 million a year-ago.
- In: General